Kosel Medical Secures Nearly RMB 100 Million in Series B+ Financing to Accelerate Global Platform Strategy in Vascular Intervention

Recently,Kossel Medtech (Suzhou) Co., Ltd. (hereinafter referred to as "Kossel Medtech")Announced the completion of a nearly 100-million-yuan B+ round of financing. This round of financing was led by a well-known investment institution in China.IronstoneLeading investment,SU High-tech FinanceContinuous Additional Investment,Yuan Yong InvestmentFollow-on investment, the funds will be used for core product R&D, global market promotion, and production capacity expansion. This round of financing demonstrates the investors' full recognition of Kossel's rapid and high-quality development and future potential, and also lays a solid foundation for Kossel to consolidate its platform-based layout.

Kossel Medtech, founded in 2013, has become a platform enterprise in the field of vascular interventional devices, forming a "one core, three wings" business layout: the parent company builds a "one-stop" treatment system for peripheral interventions (covering venous/arterial); its subsidiary Haiyu Xincheng focuses on the cardiac electrophysiology sector (providing comprehensive solutions for treating tachyarrhythmia); its subsidiary Mixin Medtech concentrates on the research and development of coronary intervention products and the localization of overseas technologies; its subsidiary Haiwang Medtech is committed to overcoming the "bottleneck" technology of medical core raw materials.

Kossel Medtech actively implements the "Local Base, Global Reach" overseas strategy. In 2021, it acquired Irish company Micell, obtaining its global clinical data from thousands of cases and proprietary coating technology, marking a solid first step in globalization. The company has completed product registration in over 20 countries abroad and plans to establish more overseas subsidiaries and offices. Global sales will officially commence in 2024, with scaled overseas expansion expected by 2026.

Kossel Medtech (Suzhou) Co., Ltd. has invested over 300 million yuan in R&D, building a rich technical platform. It has a nearly 100-person team for R&D, processes, and registration, owns hundreds of domestic and international invention patents (including nearly 100 PCT patents), and holds more than 40 Class III medical device registration certificates in China and abroad (nearly 20 of which are international certificates). Two innovative products have been successfully commercialized, achieving a leap from domestically produced alternatives to independent innovation. Kossel Medtech has complete market, academic, and sales teams, with nearly 2,000 cooperative hospitals in China, and has become a recognized brand in the industry.

Kossel Medtech is standing at a new starting point of development, striding towards the goal of becoming a leading enterprise in pan-vascular interventional devices. It is believed that in the future, Kossel Medtech will provide more excellent clinical solutions and bring greater benefits to patients with more innovative products, a larger market share, and more outstanding contributions to the industry.[Kossel Medtech will take this financing as an opportunity to accelerate the advancement of the "Three-Five" strategy – achieving full internationalization in the three major fields of peripheral, coronary, and electrophysiology by 2028. It aims to build a global vascular interventional diagnosis and treatment solutions platform, committed to becoming a global medical device enterprise in the pan-vascular intervention field, allowing innovative technologies to benefit patients worldwide.]

Ironstone: We invest in Kossel Medtech because of its platform-based layout, international strategy, rich product pipeline, long-term high R&D investment, and strong marketization capabilities, further optimizing its strategic layout and accelerating the process of domestic and international market expansion. We highly appreciate the strategic vision and management capabilities of Kossel Medtech's management team and look forward to seeing them continuously achieve new milestones on their path to realizing strategic goals.

Sugaoxin Jinkong: Kossel Medtech, as a vascular intervention platform enterprise rooted in Suzhou New District and oriented globally, has achieved efficient implementation of multiple innovative medical-engineering combination products under the background of continuously growing vascular diagnosis and treatment demands. With a gradient product matrix covering core areas such as peripheral, coronary, and electrophysiology, combined with strong R&D, manufacturing, and commercialization capabilities, Kossel Medtech stands out. As an investment institution that has long focused on medical devices and advanced manufacturing, we highly recognize the team's strategic determination and innovation strength in deeply cultivating the industry. Continuous additional investment not only affirms the value of its existing product pipeline but also reflects positive expectations for its long-term competitiveness in continuous innovation, domestic substitution, global layout, and lean manufacturing. We look forward to Kossel Medtech constantly launching innovative devices with prominent clinical value under the leadership of the founding team, bringing more benefits to patients in China and around the world. We will also fully support the company in becoming an internationally leading vascular intervention enterprise.

Yuan Yong Investment: We are an investment institution established by alumni of Nanjing University. Kossel Medtech, as an alumni enterprise of Nanjing University, demonstrates the deep integration advantages of "industry-academia-research". Our investment in Kossel Medtech is not only based on the recognition of alumni identity, but more importantly, we see Kossel Medtech's down-to-earth "sincerity and simplicity" and dream-bearing "grandeur". We firmly believe that Kossel Medtech will become a benchmark enterprise among Nanjing University alumni.